SEC EDGARNov 9$NXTC

ADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $24K of NXTC (indirect holdings)

ADAR1 Capital Management, LLC purchased 4,686 indirectly-held shares of NextCure, Inc. (NXTC) at $5.10 across 2 trades over 2026-11-05 to 2026-11-06. Filed jointly with Schneeberger Daniel (10% owner).

Original reporting

SEC EDGAR · ADAR1 Capital Management, LLC, Schneeberger Daniel

Published Nov 9, 2026, 9:19 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 9, 2026, 9:26 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$NXTC

Neutral

high confidence

Mentioned

$NXTC

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$NXTCNeutralLow

Why it matters

The disclosed purchase is small relative to market cap, so price impact is expected to be limited.

Market read

Insider buying signals confidence but the modest size limits trading relevance.

What to watch

Potential upcoming clinical data could make the insider stake more meaningful.

Relevance 3/10Novelty 3/10Timing: post‑market today

Background

Form 4 filings disclose insider transactions and are primary sources of corporate ownership changes.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NXTCNeutralHigh confidence

Context

SEC Form 4 shows ADAR1 Capital Management purchased 4,686 shares of NextCure at $5.10 per share, increasing its holding to 737,956 shares.

Expected impact

minor upward pressure as the market prices in insider confidence

Evidence & confidence

The transaction is modest in size ($24K) and unlikely to move the stock significantly, but insider buying can be viewed positively.

Market effects

Sector

Minimal impact on the biotech sector; insider activity is routine.

Regional

No discernible regional effect.

Global

Limited to investors tracking NextCure.

Counterpoint

What could challenge this read

The purchase may be a routine portfolio adjustment rather than a strong endorsement.

Key entities

company
NextCure, Inc.
Biopharmaceutical company developing cancer therapies.
investment_firm
ADAR1 Capital Management, LLC
Investment manager acting as a 10% owner of NextCure.

Read at source ← All news

$NXTCHigh

NextCure, Inc. (NXTC): Reports Third Quarter 2026 Financial Results

NextCure, Inc. (NXTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results – Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing – S-4 Declared Effective by SEC; S

SEC EDGAR 8-KNov 10

$LNTHMed

Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

rttnews.comAug 15

$NXTCMedAI 8/10

RTW Bio's Avere To Merge With NextCure

RTW Biotech Opportunities said its portfolio company Avere Therapeutics will merge with NextCure Inc. in an all-stock deal expected to close by year-end. The combined firm will trade on Nasdaq as Avere Therapeutics under AVRX. Avere plans $820M in private placements, including $5.9M from Avere, to fund AVR-001 Phase 2b psoriasis, Phase 3 psoriasis, and Phase 2b ulcerative colitis.

rttnews.comAug 12

$NXTCMedAI 8/10

Avere Therapeutics to merge with NextCure Inc.

RTW Biotech Opportunities said private portfolio company Avere Therapeutics will go public via an all-stock reverse merger with NextCure Inc., expected by year-end. Avere plans $320 million and $500 million private placements totaling $820 million. The combined company will trade on Nasdaq as Avere Therapeutics, Inc. under ticker AVRX, funding AVR-001 through psoriasis Phase 2b and Phase 3, and ulcerative colitis Phase 2b.

investegate.co.ukAug 12

$NXTCMed

NextCure Reports Q2 Loss As Proposed Avere Merger Reshapes Strategic Direction

NextCure (NXTC) reported Q2 2026 net loss of $14.9M, narrower than $26.8M a year earlier, with lower R&D and G&A expenses. It also recorded $5.1M asset impairments. NextCure said its all-stock merger with Avere Therapeutics is expected to close in H2 2026, with the combined firm trading as AVRX and Avere pursuing about $320M gross private financing.

rttnews.comAug 10